Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus across all key financial metrics, driven by a 15% YoY surge in the Growth Portfolio and 22% growth in Eliquis. Revenue reached $13.0B vs. the $11.7B expected, while non-GAAP EPS of $2.04 far exceeded the $1.60 consensus. Bolstered by broad-based momentum, management raised full-year FY26 revenue guidance to $49B-$50B and increased the non-GAAP EPS outlook to $6.75-$7.00.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Bristol Myers Squibb(BMY) the Revenue is 12.97 B (+5.74%), Beat estimate;the EBIT is 5.12 B (+48.36%), Beat estimate;the EPS is 1.62 (+153.1%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
12.97B5.74%
11.74B4.34%
+1.24B10.08%
EBITExceed expectations
5.12B48.36%
4.18B21.09%
+0.94B27.27%
EPSExceed expectations
1.62153.13%
1.3124105.07%
+0.307648.06%
Upcoming earnings report - FY2026 Q3 Earning Release
Available dateOct 29, 2026
Estimate Revenue12.66 B
Estimate EBIT4.538 B
Estimate EPS1.4612
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf